



CROs: Please note that a number of items are highlighted in this template agreement. These highlighted items should be replaced with the relevant information by you. Please replace information only as directed in the highlighted area, not the information without highlight or in parentheses. Agreements should not be signed if any portion remains in highlight or if there are any other internal comments or marked revisions in the document.

Takeda Sponsored Clinical Trial Agreement

A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for The Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions-

Formatted: Font: Bold, Complex Script Font: Bold

Takeda Development Center Americas, Inc. Clinical Protocol No. TAK-226-3001

THIS TAKEDA SPONSORED CLINICAL TRIAL AGREEMENT (the "Agreement") is made as of 20, 2026 ("Effective Date"), by and among **IQVIA RDS (INDIA) PVT. LTD., a contract research organization** having a place of business at Omega Embassy Tech Square, Marathahalli-Sarjapur Outer Ring Road, Kadubeesanahalli, Bangalore - 560103, Karnataka, India ("CRO"), **TATA MEDICAL CENTER** INSERT NAME OF INSTITUTION, having a place of business at 14 Major Arterial Road (EW), Newtown, Rajarhat, Kolkata - 700160, West Bengal, India Insert address of Institution ("Institution") and **DR. ARIJIT NAG**, Tata Medical Center, 14 Major Arterial Road (EW), Newtown, Rajarhat, Kolkata - 700160, West Bengal, India INSERT NAME OF PRINCIPAL INVESTIGATOR, (the "Investigator" and together with the Institution, the "Site"). For purposes of this Agreement, each of CRO and the Site may be referred to as a "Party" and together as the "Parties."

RECITALS:

WHEREAS, **Takeda Development Center Americas, Inc.** ("Sponsor") desires to obtain the services of the Site to conduct a clinical trial on Sponsor's investigational drug identified as **Elritercept TAK-226 (formerly KER-050)** (the "Study Drug");

WHEREAS, Sponsor has designated or may designate CRO and/or other organization(s) (collectively, "Designee(s)") in the performance of services for Sponsor, and the Site shall permit such Designee(s) to perform any or all of Sponsor's obligations under this Agreement;

USE THE CLAUSE BELOW WHEN INVESTIGATOR IS AN EMPLOYEE OF INSTITUTION

WHEREAS, the Investigator is an employee of Institution, experienced in the conduct of clinical research studies in humans, who shall serve as the principal investigator for the Study, as contemplated in Clause 3.3 of the Good Clinical Practices Guidelines ("GCP Guidelines") formulated by the Central Drugs Standard Control Organization and adopted by the Drugs Technical Advisory Board, for the Study (defined below);

USE THE CLAUSE BELOW WHEN INVESTIGATOR IS NOT AN EMPLOYEE

~~WHEREAS, the Investigator is a member of the medical staff of Institution with privileges to conduct research at Institution's facilities, and shall serve as the principal investigator for the Study, as contemplated in Clause 3.3 of the Good Clinical Practices Guidelines ("GCP Guidelines") formulated by the Central Drugs Standard Control Organization and adopted by the Drugs Technical Advisory Board, for the Study (defined below);~~

WHEREAS, the Site has reviewed sufficient information regarding the Protocol (defined below) to evaluate its interest in participating in the Study, and the Site is equipped to undertake the Study and desires to perform the Study on the terms and conditions set forth herein;

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein, the Parties, intending to be legally bound, have entered into this Agreement and do specifically agree as follows:

1. Study Protocol.

A. The Site will conduct the study entitled "**A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritcept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions**" (the "Study") at Institution in accordance with the protocol, a copy of which was previously provided, incorporated herein by reference (the "Protocol"). The Protocol sets forth the clinical research activities and responsibilities to be undertaken by the Parties. CRO, at the direction of Sponsor, shall have the right to amend and/or supplement the Protocol from time to time on written notice to Investigator and/or Institution. If any term of this Agreement regarding the medical or scientific conduct of the Study conflicts with any term of the Protocol, the Protocol shall control. For all other matters, this Agreement shall control.

B. If the Investigator determines in his/her best medical judgment that a deviation from the Protocol is necessary to eliminate an apparent immediate hazard to the health or safety of any subject participating in the Study, he or she may deviate from the Protocol; provided, however, that the Investigator shall immediately notify Sponsor in writing of the facts giving rise to the need for the deviation and the alternate procedures followed and promptly report such deviations to the IEC. Except as provided for in the previous sentence, the Investigator shall not amend or deviate from the Protocol without the prior written approval of Sponsor.

2. Conduct of Study.

A. The Parties shall, and shall ensure that their employees and agents shall, conduct the Study in compliance with (i) New Drugs and Clinical Trials Rules, 2019 and its amendments and associated regulations, (ii) all generally accepted professional standards, (iii) GCP guidelines, (iv) the ICH Harmonized Tripartite Guideline for Good Clinical Practice ("ICH Guidelines") (v) any and all federal, national, state, local or other jurisdictional laws, rules, regulations, policies, guidelines, guidance, and governmental requirements, including without limitation, all conditions imposed by an ethics committee ("IEC") that may be applicable to the Parties, Study Personnel (defined below), and/or the Study (collectively, "Applicable Law").

B. Institution and/or Investigator may use sub-investigators, co-investigators, other employees of Institution, and contractors to perform Study-related services under this Agreement (together with Investigator, "Study Personnel"). Institution shall ensure that:

i. All Study Personnel are adequately informed about the Protocol and their Study-related duties and functions and perform their Study responsibilities and fulfill their obligations under this Agreement, including adherence to the Protocol and the Investigator's instructions;

ii. All Study Personnel have the necessary licenses and certifications as may be required to perform their Study responsibilities;

iii. Investigator and all Study Personnel are under an obligation to assign all rights in any intellectual property invented during the course of their employment to Institution.

iv. Any Study Personnel not employed by Institution shall comply with the same terms that bind Investigator hereunder.

v. Any Study Personnel not employed by Institution shall be obligated to assign their rights in any Developments to Institution.

C. Without limitation of the foregoing, Institution further agrees that, in the performance of the Study, Institution and Institution's employees and agents shall:

i. provide to each potential subject verbal and written information about the risks, benefits, and requirements associated with Study participation, as well as communicate to potential subjects all other information necessary to obtain valid informed consent and provide an answer to any queries related to the Study as asked by the subject, and obtain in advance from each Study subject a signed and dated written informed consent form that has received prior approval from the IEC and Sponsor and that is consistent with the Protocol and this Agreement;

ii. require that no subject in the Study may participate concurrently in any other clinical study in which a study drug is given. Should Institution or Investigator become aware of any such concurrent study participation, it shall notify Sponsor promptly;

iii. maintain and prepare records relating to the Study and subjects participating in the Study as specified in the Protocol;

iv. complete all subject case report forms ("CRFs") using the form(s) provided by or on behalf of Sponsor, whether recorded on paper or in digital format, review the CRFs to assure their accuracy and completeness, assist the representatives and clinical monitors of Sponsor in promptly resolving any discrepancies or errors on CRFs, and, provided subject confidentiality is maintained, assist in performing audits of original subject records, laboratory reports, or other raw data sources for the purpose of verifying data recorded on the CRFs;

v. ensure that all data, including signatures, supplied to Sponsor will meet the principles of ALCOA+ (attributable, complete, legible, original, accurate, contemporaneous, permanent, readily retrievable), and further certify that appropriate controls are established to mitigate the risks related to intentional or unintentional falsification of data and signatures as required by Applicable Law;

vi. cooperate with Sponsor and its Designee in all of their efforts to support and monitor the Study, including without limitation, allowing Sponsor on-site access to the facilities where the Study is being conducted and any and all records and other documents associated with the conduct of the Study as reasonably requested by Sponsor, providing all requested documentation in a timely and organized manner, and keeping Sponsor fully apprised of the progress of the Study;

vii. record all adverse events on the Adverse Events page(s) of the CRFs and promptly report all adverse events and serious adverse events to CRO, Sponsor and IEC in accordance with Applicable Law and the Protocol and cooperate with Sponsor in identifying and resolving unexpected occurrences involving the Study Drug or its use in the Study;

viii. retain all records relating to the Study, for the period required by Applicable Law, and prior to the Institution or Investigator's disposition of any Study records, the Site shall provide prior written notice to Sponsor, and upon Sponsor's request and at Sponsor's reasonable expense, the Site shall either retain such Study records for the period specified by Sponsor or send such records to Sponsor, as designated by Sponsor;

ix. cooperate with and support the Sponsor with regard to the relevant applications or communications with the relevant IEC;

x. obtain the prior written approval of CRO, Sponsor and the IEC of subject recruitment procedures, including the content of any communication soliciting subjects for the Study (including any changes) and any other written or verbal information to be provided to the subjects, which must comply with Applicable Law; and

xi. conduct the Study solely at Institution's facilities; the location for the conduct of the Study may not be changed without Sponsor's prior written consent;

xii. promptly report to the CRO, Sponsor and IEC new information that may adversely affect the safety of the subjects or the conduct of the Study;

xiii. provide copies of any relevant document as may be requested by the Sponsor, CRO, the IEC or the regulatory authorities; and

xiv. familiarize themselves with the safety, efficacy and appropriate use of the Investigational New Drug as described in the Protocol, Investigator's Brochure and other information sources provided by the Sponsor from time to time.

D. The Institution further represents and warrants to Sponsor that:

i. neither the Institution, nor any of the Institution's employees or agents performing the Study, (1) are under any contractual or other obligations or restrictions that are inconsistent with the Institution's obligations under this Agreement, or (2) have a financial or other interest in Sponsor or the outcome of the Study that might interfere with their independent judgment, or (3) are under investigation by any regulatory authority, for debarment or any action in relation to clinical research, or (4) are presently debarred, disqualified, or deemed ineligible to conduct clinical research or to receive investigational drugs or devices as a clinical investigator under any Applicable Law. The Institution will notify Sponsor immediately (a) if Institution, the Investigator, or any of its employees or agents become debarred, disqualified, or deemed ineligible by any court or regulatory agency, or (b) upon any inquiry concerning or the commencement of any debarment or disqualification proceeding regarding any such person, the Investigator, or Institution, together with any other information known to the Site that is relevant to such proceedings or actions;

ii. The Institution shall properly supervise all persons performing the Study under its direction and shall ensure that such persons comply with the terms of this Agreement.

E. In conducting the Study for Sponsor, the Institution and the Institution's employees, agents, and contractors (i) shall not offer to make, make, promise, authorize or accept any payment or give anything of value, including without limitation *bribes, either directly or indirectly* to any public official, regulatory authority or anyone else for the purpose of influencing, inducing or rewarding any act, omission or decision in order to secure an improper advantage, or obtain or retain business; and (ii) shall comply with all applicable anti-corruption and anti-bribery laws and regulations. Institution or Investigator shall notify Sponsor immediately upon becoming aware of any breach of Institution's and/or Investigator's obligations under this Section.

3. Investigator; Replacement.

A. Investigator shall provide Sponsor with a copy of the Investigator's current curriculum vitae.

B. Investigator shall provide Sponsor with sufficient accurate financial disclosure information to permit Sponsor to submit a complete and accurate certification or disclosure statement as required by Applicable Law, and will promptly update the information if any relevant changes occur during the course of the Study and for one (1) year following completion or termination of the Study. Investigator consents to the disclosure by Sponsor of such financial information to the U.S. Food and Drug Administration ("FDA") and, if required, other regulatory authorities. Investigator shall cooperate with Sponsor to provide any additional information required by the FDA and/or such other regulatory authorities in connection with the Study.

C. If the Investigator becomes either unwilling or unable to perform the duties required by this Agreement, Institution shall promptly notify Sponsor, and shall cooperate to find a replacement investigator acceptable to Sponsor (a "Replacement Investigator"); provided, however, that the Site shall continue to be responsible for fulfilling the obligations of this Agreement until a Replacement Investigator is appointed. If

an acceptable Replacement Investigator is not found within thirty (30) days (or such longer period as mutually agreed upon by the Parties), CRO may terminate this Agreement in accordance with the terms herein. If a Replacement Investigator is designated, such Replacement Investigator shall be bound by all terms of this Agreement that are applicable to the Investigator, and the Parties shall amend this Agreement accordingly.

D. If Sponsor or CRO requests, Investigator shall attend and participate in an investigator's meeting or other initiation meeting. Sponsor will reimburse Investigator for reasonable and necessary travel and lodging expenses incurred to attend such meeting(s). The receipts for such meeting(s) must be submitted to Sponsor or Sponsor's Designee within sixty (60) days of the date of the meeting. From time to time Sponsor may take photographs or create audio and/or, video recordings in connection with investigator meetings. Investigator hereby gives Sponsor (or anyone acting with Sponsors authority) permission to make, take or create photographs, video and/or audio recordings and transcriptions in connection with such meetings or Study related activities and to use, store, copy, display, reproduce transmit and publish such records.

4. Term; Study Initiation; Completion/Termination

A. This Agreement will become effective on the date of approval of the Study by the Drugs Controller, India or on the date on which it is last signed by the parties, whichever date is later ("Effective Date"). Consequently, the Institution and Investigator will not be permitted to screen patients, randomize patients, receive the Study Drugs or receive any start up payment until the validity date of this Agreement is reached. The Agreement shall continue until completion of all obligations herein, including without limitation receipt by Sponsor of all Study data and resolution of all corresponding queries in a form acceptable to Sponsor ("Completion"), unless otherwise terminated in accordance with this Agreement.

B. The Investigator shall deliver copies of the Drugs Controller, India and IEC approval letters to Sponsor. If Drugs Controller, India or IEC approval is not obtained, this Agreement shall be null and void. The Site shall promptly notify Sponsor if Drugs Controller General India or IEC approval for the Study is lapsed, suspended, or withdrawn in whole or in part.

C. No subject may be enrolled in the Study without the Investigator first obtaining an approved informed consent signed by or on behalf of each subject. The Site shall not request an informed consent from any subject or allow any subject to participate in the Study prior to the initiation of the Study in accordance with the Protocol and the terms of this Agreement.

D. Investigator shall ensure the unbiased selection of an adequate number of suitable subjects according to the Protocol. The Site acknowledges that Sponsor and CRO reserve the right to limit entry or enrollment of subjects at any time.

5. Payment Terms and Budget.

A. In consideration for performance of the Study, Sponsor will compensate Institution in accordance with the payment terms and budget set forth in Schedule A attached hereto and made a part hereof (the "Budget"). No other benefits or compensation, beyond those expressly included in the Budget, or as otherwise approved by Sponsor in advance in writing, will be provided by Sponsor to Institution. Absent a good faith dispute, payments shall be made by Sponsor or CRO in accordance with the Budget following receipt of a detailed invoice from Institution, which invoice shall be consistent with the provisions set forth in the Budget. All invoices will be itemized as set forth in the Budget. Any expenses, including travel expenses, for which reimbursement is sought, shall be paid only if (i) the request for reimbursement for such expenses is accompanied by original receipts and (ii) Sponsor has expressly agreed to reimburse such expenses in writing or in the Budget. The last payment due will be made by Sponsor or CRO after the Site completes all of its obligations hereunder, and Sponsor or CRO has received all completed CRFs, all deliverables defined in the Protocol, and all other data and rights to which Sponsor or CRO is entitled under this Agreement. The terms of the Budget may be modified only upon the prior written consent of the Parties. All payments made to a payee under this Agreement are subject to Tax Deducted at Source ("TDS") in accordance with Indian tax laws, as amended from time to time. CRO will deduct the tax at the

time of making payments unless a valid Certificate (Form 15 AA – for no TDS) from the tax authority is made available.

B. The Parties acknowledge and agree that the amounts payable by Sponsor under this Agreement represent the fair market value of the covered costs associated with the Study and no part of any consideration paid hereunder is a prohibited payment for the recommending or arranging for the referral of business or the ordering of items or services; nor are the payments intended to induce illegal referrals of business.

C. For all services required under the Protocol for which Sponsor has agreed to provide compensation, Sponsor, through CRO, will be the sole source of compensation. With the exception of third party payors (e.g. *insurers*), no part of the Study shall be conducted with funding from any third parties, including without limitation, any government or government agency funding, without the prior written consent of Sponsor. Neither Institution nor Investigator will seek reimbursement from any government healthcare program or third party payor for amounts paid by or on behalf of Sponsor, or for any materials that were provided by or on behalf of Sponsor at no cost to Institution or Investigator (such as the Study Drug(s)).

D. The Site understands that Sponsor or CRO will disclose to relevant governmental authorities the payments made by or on behalf of Sponsor to the Site under this Agreement, as well as the purpose and nature of such payments, to the extent that Sponsor deems necessary under Applicable Law.

6. Confidentiality.

A. All information (including without limitation, verbal, written, and electronically stored or transmitted information), materials, and documents provided to the Site by or on behalf of Sponsor in connection with the Study, including without limitation preclinical data and CRFs, and Study Results shall be considered "Confidential Information." Confidential Information also includes without limitation, the Protocol, the Investigators' Drug Brochure, Study correspondence, and Study Results; provided, however, that the Site may use and/or publish Study Results in accordance with the terms of this Agreement. The Site hereby agrees that it: (i) shall maintain in strict confidence all of the Confidential Information, (ii) shall not disclose or disseminate Confidential Information to any third party, (iii) shall not use the Confidential Information for any purpose other than the performance of the Study, and (iv) shall safeguard the Confidential Information using the same degree of care, but no less than a reasonable degree of care, as the Site uses to protect its own confidential information. Such Confidential Information shall remain the exclusive confidential and proprietary property of Sponsor and shall be disclosed only on a need-to-know basis and only to the Site and the Site's employees and agents. The Site agrees to ensure that each of the Site's employees and agents rendering services hereunder treat the Confidential Information as confidential consistent with the terms hereof.

B. The foregoing obligations shall not apply to Confidential Information that:

- i. is or becomes publicly available through no fault of the Site;
- ii. is lawfully disclosed to the Site by a third party entitled to disclose such information without any obligation of confidence;
- iii. is already known to the Site prior to disclosure hereunder, as shown by the Site's prior written records; or
- iv. was developed by the Site without the use of any Confidential Information, as evidenced by the Site's prior written records.

C. In the event that Confidential Information is required to be disclosed by law or regulation, the Site shall (i) timely notify Sponsor and provide Sponsor an opportunity to object to such disclosure, prior to making any such disclosure, and (ii) use all reasonable efforts to limit the disclosure and maintain the confidentiality of such Confidential Information to the extent reasonably possible.

D. Upon demand by Sponsor, the Site shall return all Confidential Information, including all copies thereof, to Sponsor; provided, however, that one (1) copy of such Confidential Information may be retained by Institution in its confidential files for compliance purposes only.

7. **Data Protection.** The Parties agree to the terms and conditions set forth in Schedule B.

8. **Use of Study Results.** Subject to Applicable Law, Sponsor shall have the unrestricted right to use and publish, any data and information from the Study without the consent of Investigator or Institution, provided that Sponsor maintains subject confidentiality. The Site will not use data generated during the Study or results of the Study for any purpose other than care of a subject, for internal research purposes, or for publication subject to Article 9, below. For the avoidance of doubt, internal research purposes means internal, non-commercial research activities that are not funded by a third party (other than a government agency). The Site shall obtain all legally required authorizations or other documentation from Study subjects to allow for disclosures of Study subjects' data to Sponsor and its Designee in accordance with this Agreement.

9. **Ownership of Data; Publication.**

A. All data, information, and results generated during the course of conducting the Study, including without limitation, the completed CRFs and any reports prepared by the Site (collectively the "Study Results") shall be the sole property of Sponsor. The Site shall have the right to publish or otherwise publicly disclose the Study Results for its own internal, bona-fide, academic, non-commercial purposes, in accordance with the terms of this article. The medical records or other Source Documents, as defined by ICH Guidelines, that support the Study Results shall remain the property of Institution.

B. If the Study is being conducted as part of a multi-center clinical trial, the first publication of the results of the Study shall be in the form of a multi-center publication authored by investigators in this Study. However, if a multi-center publication is not submitted within eighteen (18) months following Completion or termination of the Study at all sites, the Site may publish Institution's Study Results in accordance with this article, with due consideration to the privacy and confidentiality of data in relation to the Study subjects.

i. The Site will provide Sponsor with a copy of any proposed publication or presentation for review and comment at least forty-five (45) days prior to such presentation or submission for publication. At the expiration of such forty-five (45) day period, the Site may proceed with the presentation or submission for publication unless Sponsor has notified Investigator or Institution in writing that such proposed publication and/or presentation discloses Confidential Information. Following such notification, the Site hereby agrees to make any changes or deletions prior to publication necessary to prevent disclosure of Confidential Information (excluding Study Results). Further, upon the request of Sponsor, the Site will delay publication or presentation for an additional ninety (90) days to permit Sponsor to take necessary actions to protect its intellectual property interests.

ii. The Site will keep the proposed publication confidential during the review periods described herein and will give due consideration to all comments provided by Sponsor.

iii. Except as otherwise mutually agreed by the Parties, publications will be submitted to journals that offer public availability via Open Access (including publisher platforms/repositories and self-archiving). Open Access refers to the free at point of entry, online availability of published research output with, where available, rights of re-use according to an end user license. Sponsor encourages the publication using the Creative Commons Attribution 4.0 generic license (CC-BY 4.0) or equivalent license whenever possible, with or without embargo period, over more restrictive Creative Commons licenses such as CC-BY-NC, CC-BY-NC-ND, or others.

iv. Unless otherwise required by the journal in which the publication appears, or the forum in which it is made, authorship will comply with the International Committee of Medical Journal Editors

(ICMJE) Recommendation for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical journals. Participation as an investigator, in and of itself, does not confer any rights to authorship of publications.

10. Release of Information; Use of Name. Sponsor may disclose the name of the Site and shall provide a description of this Study on public websites (e.g., www.clinicaltrials.gov and <http://ctri.nic.in/Clinicaltrials/login.php>) consistent with and as required by Applicable Law. No Party shall use the name of any other Party in connection with any advertising or promotion of any product or service without the prior written permission of such other Party; provided, however, that the limitations contained in this article shall not apply to any documents that may be necessary or appropriate for Sponsor or the Site to provide to a federal, state, or local governmental agency or in scientific publications and grant applications. Sponsor must approve, in writing, press statements by Investigator or Institution or any of their respective employees, agents, or contractors regarding the Study or the Study Drug(s) before release of the statements.

11. Independent Contractors. In conducting the Study, the Site will each be acting as an independent contractor with respect to Sponsor and its Designee, and not as an agent, partner, or employee of Sponsor. Neither Investigator, Institution, nor any of their respective employees, agents, or contractors, shall have any authority to make agreements with third parties that are binding on Sponsor.

12. Study Drug. Biological Samples.

A. CRO or another duly authorized agent of Sponsor, shall make commercially reasonable efforts to supply Institution or Investigator with sufficient quantities of the Study Drug in a timely manner, at Sponsor's expense. All drugs/medication supplied by Sponsor will be used solely in accordance with the Protocol and may not be used for any other purposes. The Site shall comply with all laws and regulations governing the storage, disposition or destruction of Study Drug(s) and any other drug(s)/medication provided for the Study and any instructions from CRO that are not inconsistent with such laws and regulations. Investigator shall be primarily responsible for Study Drug(s)' accountability at the Institution.

B. The Site will collect, retain, use and transfer biological samples (blood, fluid and tissue samples collected from subjects enrolled in the Study, including any tangible materials derived from such samples (collectively, "Biological Samples")), only in accordance with the Protocol and the applicable informed consent.

C. The Site may collect or reserve additional quantities of Biological Samples ("Secondary Biological Samples") for use in research not described in the Protocol ("Non-Protocol Research"), provided that such collection complies with Applicable Law and separate written consent from the subjects. The Site may annotate Secondary Biological Samples with Study subject demographic information (e.g., age, gender and clinical diagnosis). Confidential Information, Study-related information (including subject's participation in the Study), Study Results or analyses thereof (such as information related to administration of, or response to, or adverse events associated with, the Study Drug) may be linked to the Secondary Biological Samples, provided that the provisions of Article 15 shall apply to such Non-Protocol Research.

D. Upon Completion or any termination of this Agreement, the Site shall deliver or dispose of Biological Samples according to Sponsor's instructions and any relevant provisions in the Protocol and applicable informed consent and shall immediately cease to use the Study Drug. All unused Study Drug shall be promptly returned to Sponsor or, at Sponsor's written request, destroyed by the Site with a certificate of destruction provided to Sponsor.

13. Inspections, Audits, and Study Monitoring.

A. **Regulatory Inspection.** The Site shall notify Sponsor and its Designee promptly of any inquiries, correspondence, or communications with or from the FDA or any other governmental or regulatory authority relating to the Study. If a regulatory authority requests permission to or does inspect the Site's facilities or research records relating to the Study, the Site will cooperate with the regulatory authority's representative(s) and permit such inspection. The Site shall provide to Sponsor copies of all materials that

the Site receives, obtains, or generates in connection with any such inspection or in connection with any communications from regulatory authorities.

B. Sponsor Inspection/Audit.

i. The Site agrees to permit representatives of Sponsor (including monitors, auditors, and inspectors), upon reasonable notice and during normal business hours, to examine (i) the facilities where the Study is being conducted, (ii) raw Study Results including original Source Documents (as defined by current ICH Guidelines), regardless of media, if allowed under the terms of the informed consent, (iii) Electronic Data Capture ("EDC") equipment and/or EDC documentation system, and (d) any other relevant information (and to make copies) necessary for Sponsor to confirm that the Study is being conducted in conformance with the Protocol and the data protection requirements of Schedule B, and in compliance with Applicable Law.

ii. If any such inspection discloses any non-compliance with this Agreement, Sponsor and/or CRO is entitled to secure compliance or discontinue shipments of Study Drug(s) and terminate the Site's participation in the Study and notify the regulatory authorities about such discontinuance.

14. Termination Prior To Completion.

A. This Agreement may be terminated in whole or in part prior to Completion upon written notice as follows:

i. by any Party, upon written notice if (1) the authorization and approval to conduct the Study is irrevocably withdrawn by the applicable health authority or Institution's IEC; or (2) the Sponsor or Investigator determines continuation of the Study will compromise the safety of the Study subjects and such determination is based on reasonable medical judgment;

ii. by Sponsor (1) upon notice if the Investigator is unwilling or unable to serve as the principal investigator and the Parties are not able to agree on a substitute pursuant to the terms of this Agreement; (2) upon notice if the Site fails to perform the Study in accordance with the terms of the Protocol (excluding permitted deviations pursuant to the Protocol and under the terms of this Agreement), or Applicable Law; or (3) upon thirty (30) days written notice.

iii. by the Site, upon thirty (30) days written notice, in the event of a material breach of this Agreement by Sponsor and Sponsor's failure to remedy such breach within such thirty (30) day period.

B. In the event of the premature termination or suspension of the Study, the Investigator and Institution agree to promptly inform the IEC and the local regulatory authorities about such termination or suspension. In the event that the Study proceeds to completion, Investigator shall inform the completion of the Study to the Institution, CRO, Sponsor and IEC.

C. In the event of termination of this Agreement prior to Completion, the Site shall, upon notice of termination, make all reasonable efforts to minimize incurring further costs. In the event of such early termination, payments will be made for all services required by the Protocol that have been performed up to the effective date of termination and any reasonable, documented non-cancelable costs which were incurred by Institution or Investigator in connection with the Study as required under the Protocol and contemplated in the Budget. If the payments exceed the amount owed for services performed under the Protocol, Institution shall promptly return the excess balance to CRO.

D. Immediately upon receipt or delivery of notice of termination, the Site shall (i) comply with post-termination procedures included in the Protocol, if any, and (ii) unless otherwise directed by Sponsor, cease enrolling subjects into the Study and cease the Study-related treatment of subjects already enrolled in the Study (unless the safety of such enrolled subjects could be compromised thereby).

E. Upon Completion or termination of this Agreement for any reason, the Site will furnish to Sponsor all CRFs, and all Sponsor materials. Confidential Information and materials will be returned, at Sponsor's instruction, to Sponsor, except for record copies or samples which the Site is required by law to retain. Within thirty (30) days of termination of this Agreement or Completion of the Study (whichever comes first), Investigator will submit a final written report of the Study to Sponsor.

F. Neither Sponsor nor CRO shall be responsible to the Site for any lost profits, lost opportunities, or other consequential damages.

15. Patent Rights and Inventions.

A. It is expressly agreed that no Party transfers by operation of this Agreement to any of the other Parties any right in or license to any patents, copyrights, or other proprietary right owned as of the Effective Date of the Agreement or arising outside of the research conducted under this Agreement.

B. The Site acknowledges that the idea for the Study was conceived and developed by Sponsor and that Sponsor approached Institution and/or Investigator to perform the Study. The Site will fully and promptly disclose in writing to Sponsor any inventions and developments discovered by Institution or Investigator, any sub-investigator, co-investigator or any of their respective employees, agents, or contractors (1) in the conduct of the Study, (ii) as a result of using Sponsor's Confidential Information; or (iii) as a result of using Secondary Biological Samples in non-protocol research (collectively "Developments"). Sponsor shall have sole ownership and rights in any Developments. The Site shall fully cooperate with Sponsor to vest rights therein in Sponsor and to obtain patents or other legal protections thereon.

16. Indemnification; Insurance.

A. Sponsor Indemnification. Sponsor agrees to indemnify, defend and hold harmless Institution, its trustees, officers, employees, staff, subcontractors, and agents ("Institution Indemnitee(s)") against any third party claim (each, a "Claim") arising out of: (i) the negligence or willful misconduct of Sponsor (ii) any theory of product liability concerning the Study Drug, or (iii) any side-effect or adverse reaction, illness, or injury directly resulting from use of the Study Drug in the Study or a procedure administered in accordance with the Protocol, or (iv) use of Study data or the Study Results. The foregoing indemnity will not apply to the extent a Claim arises out of: the negligence, malpractice, or willful misconduct of any Institution Indemnitee or the failure of any Institution Indemnitee to adhere to the terms of this Agreement, the Protocol, or any written instructions from Sponsor, or to comply with any Applicable Law or governmental requirements, it being understood that (x) the administration of any substance in accordance with the Protocol and any written instructions of Sponsor shall not constitute negligence or malpractice for purposes of this Agreement, and (y) a Protocol deviation that is medically necessary to protect the health or safety of a Study subject and is consistent with prevailing standards of medical care shall not constitute negligence, willful misconduct or malpractice by the Institution Indemnitees.

B. Institution Indemnification. Institution agrees to indemnify, defend, and hold harmless the Sponsor, its directors, officers, employees, staff, and agents (the "Sponsor Indemnitees") against any Claim arising out of (i) the negligence, omission, or willful misconduct of any Institution Indemnitee or (ii) the failure of any Institution Indemnitee to adhere to the terms of this Agreement, the Protocol, or any written instructions from the Sponsor or its designee, or to comply with any Applicable Law or governmental requirements.

C. Indemnification Procedure. The Party or Parties seeking indemnification under this article shall (i) give written notice to the indemnifying Party within five (5) business days after (1) receiving any Claim or (2) learning of any potential Claim; (ii) permit the indemnifying Party to assume the defense and/or disposition of any such Claim or related litigation, provided that counsel selected by such indemnifying Party is reasonably acceptable to the Party or Parties seeking indemnification; and (iii) cooperate with the indemnifying Party in all reasonable respects with regard to the defense of such Claim, with reasonable out-of-pocket costs of the Party or Parties seeking indemnification to be reimbursed by the indemnifying Party. The indemnifying Party under this article shall not enter into any settlement agreement with a claimant without the prior written permission of the Party or

Parties seeking indemnification, which permission shall not be unreasonably withheld. The indemnified Party shall have the right to select and obtain representation by separate legal counsel, provided that such indemnified Party shall bear all costs and expense related to such separate representation.

D. Insurance. The Site represents and warrants that it has and will maintain appropriate insurance, including malpractice insurance, in amounts sufficient to pay all claims arising from its activities or obligations under this Agreement. Sponsor represents that it has and will maintain appropriate insurance and/or self-insurance in amounts sufficient to respond to events that may occur in the conduct of the Study and for which Sponsor may be liable pursuant to applicable laws. Each party will provide, upon written request, copies of documentation evidencing the existence of such insurance (or in the case of Sponsor, self-insurance).

17. Subject Injury.

A. Sponsor, through CRO, shall reimburse Institution for all reasonable and customary costs incurred by the Site and associated with the diagnosis of an adverse event involving the Study Drug(s) or a Protocol procedure.

B. Sponsor, through CRO, shall reimburse Institution all reasonable and customary costs incurred for treatment of a bodily injury to a subject injured as a direct result of administration of the Study Drug or undergoing a Study-related procedure in accordance with the Protocol. Sponsor shall not provide payment for costs to the extent that they are attributable to:

i. the failure of the Site, or any Site personnel, to adhere to the terms of the Protocol or any of Sponsor's written instructions relative to the use of the Study Drug, or to comply with applicable FDA or other governmental requirements, unless such failure is consistent with generally accepted standards of clinical research and medical practice relating to the benefit, safety, and well-being of the Study subjects or is otherwise reasonably necessary for the safety of such a subject, all as determined in good faith by the Investigator;

ii. any negligence or wrongful act or omission, or willful malfeasance, of the Site or any other Site personnel providing services on behalf of the Site hereunder; or

iii. the subject's primary disease or any concurrent disease not caused by the administration of the Study Drug in accordance with the Protocol.

C. The Site represents and warrants that it will not bill the subject's insurer for any costs paid by Sponsor for treatment of an injury as described above. Sponsor will not pay for any costs already covered by a third party.

18. Complete Agreement; Amendment; Notice. This Agreement represents the entire understanding between the Parties, and supersedes all other agreements, express or implied, between the Parties concerning the subject matter hereof. This Agreement may not be amended or modified in any manner except by a written document signed by authorized representatives of the Parties. Any notice to be given hereunder shall be given by personal delivery, by recognized express courier, or by registered or certified mail, return receipt requested. Such notice shall be addressed to a Party at the address set forth below, except as set forth in Schedule A. Any Party may change its address for notice by giving written notice of such change to the other Parties.

To CRO/Designee: IQVIA RDS (INDIA) PVT. LTD.
Omega Embassy Tech Square, Marathahalli-Sarjapur Outer Ring Road,
Kadubeesanahalli, Bangalore - 560103, Karnataka, India

IQVIA Inc.
Global Legal Department
100 IMS Drive
Parsippany, NJ 07054 USA
USA

Attn: General Counsel
Email: officeofgeneralcounsel@iqvia.com

To Institution: **Tata Medical Center,**
14 Major Arterial Road (EW), Newtown, Rajarhat, Kolkata – 700160, West
Bengal, India
Attn: **Dr. P. Arun, CEO** **Insert Institution Name**
Insert Institution address
Attn: _____

Formatted: Font: Bold

To Investigator: **Dr. Arijit Nag**
Tata Medical Center, 14 Major Arterial Road (EW), Newtown, Rajarhat, Kolkata –
700160, West Bengal, India **Insert Investigator Name**
Insert Investigator Address

Formatted: Indent: Left: 1"

19. Binding Effect; Survival of Terms. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns. The rights and obligations of the Parties which by intent or meaning have validity beyond termination of this Agreement (including without limitation, rights with respect to ownership, patents, confidentiality, and indemnification) shall survive Completion or any termination of this Agreement.

20. Governing Law. This Agreement and all matters arising out of or relating to this Agreement shall be governed by, and construed and enforced in accordance with, the laws of England and Wales without regard to the conflicts of law provisions thereof.

21. Arbitration. Any dispute, controversy, or difference which may arise between the Parties hereto, out of or in relation to or in connection with this Agreement, or the breach or the interpretation thereof shall be amicably settled between the Parties. In the event such amicable settlement cannot be reached within fifteen (15) calendar days (or such longer period as the Parties may agree) from the date of the notice from any of the Parties requesting settlement negotiations to the other Party, such dispute shall be submitted to the International Chamber of Commerce (the "ICC") for arbitration in accordance with the Rules of Arbitration (the "Rules") of ICC in effect at the time of applying for arbitration. The arbitral award shall be final and binding upon the Parties. The arbitral tribunal shall be composed of three (3) arbitrators with one (1) arbitrator being selected by each of the Parties and the third arbitrator being selected by the two (2) arbitrators so selected by said Parties. If a Party fails to nominate arbitrator within thirty (30) days from the date of notification made to it of the other Party's request for arbitration, or if the two (2) arbitrators fail within thirty (30) days from the date of their appointment, to reach agreement on the third arbitrator, then the ICC shall appoint the arbitrator that was not nominated by the failing Party, or shall appoint the third arbitrator, as the case may be, in accordance with said Rules. The place of Arbitration shall be London. The language of the arbitration proceedings shall be English.

22. Severability. If any provision of this Agreement is held to be invalid, illegal, or unenforceable then such provision shall be enforced to the maximum extent permissible so as to effect the intent of this Agreement, all other provisions will nevertheless continue in full force and effect.

23. Assignment. Any assignment of this Agreement or any rights or obligations hereunder by Investigator or Institution to a third party shall require the prior written consent of CRO and Sponsor. Any assignment by CRO to any third party other than Sponsor or its affiliate shall require the prior written consent of Sponsor, but shall not require the approval of Institution or Investigator. Investigator, Institution and CRO hereby acknowledge that Sponsor may assign to itself or a third party responsibility for any or all of Sponsor's or CRO's rights and obligations hereunder by written notice to the Site and CRO.

24. Subcontracting. With Sponsor's prior written consent, Institution may subcontract the performance of certain of its activities under this Agreement to qualified third parties or use premises or facilities other than Institution to perform certain activities under this Agreement, provided that (i) the performance of activities by such third parties or at such facilities will comply with all applicable obligations

of this Agreement, including holding such third parties or facilities to terms at least as stringent as those to which the Site is bound hereunder with regard to the conduct of the Study, including without limitation, Study Drug(s) use, record retention, confidentiality, data and publications obligations, inventions, personal data, and publicity, (ii) Institution remains liable for performance at such facilities or by such third parties', and (iii) none of Investigator, any sub-investigator or any co-investigator has any direct or indirect financial interest in any such third parties or facilities.

25. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, and all of which, when taken together, will constitute one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement by facsimile transmission, by electronic mail in "portable document format" (".pdf" format), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, or by a combination of such means, shall be as effective as delivery of a manually executed counterpart of this Agreement.

26. Force Majeure. If the performance of this Agreement by Institution or Sponsor is prevented, restricted, interfered with, or delayed (either totally or in part) by reason of any cause beyond the reasonable control of the Parties (such as acts of God, explosion, disease, weather, war, terrorism, insurrection, civil strike, riots, or power failure), the Party so affected shall, upon giving written notice to the other Party, be excused from such performance to the extent of such prevention, restriction, interference, or delay, provided that the affected Party shall use its best efforts to avoid or remove such causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed. For purposes of this article, a lack of funds shall not be considered a cause beyond the reasonable control of the Parties.

27. List of Incorporated Schedules.

- A. Budget and Payment Schedule
- B. Data Protection Schedule

Remainder of page intentionally left blank

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives as the Effective Date defined above.

IQVIA RDS (INDIA) PVT. LTD:

By: _____
(Signature)

Name: Tanuka Ganguly

Title: Director, Global Site Activation

Date: _____

Tata Medical Center: **INSERT FULL NAME OF INSTITUTION**

By: _____
(Signature)

Name: Dr. P. Arun

Title: CEO

Date: _____

By: _____
(Signature)

Name: _____

Title: _____

Date: _____

Dr. Arijit Nag:

INSERT FULL NAME OF INVESTIGATOR

(Signature)

Name: Dr. Arijit Nag

Title: Principal Investigator

Date: _____

By: _____

Takeda Clinical Trial Agreement (India) CRO Inst (Inv) v.July2025 _____ Confidential

Study No.: TAK-226-3001

Tata Medical Center Dr. Arijit Nag_03/FEB/2026_FinalInstitution-Name_Pi-Name_DD/MMM/YYYY_Draft/Final

Page 14 of 38

(Signature)

Name:

Title:

Date: _____

Schedule A

BUDGET & PAYMENT SCHEDULE

BUDGET & PAYMENT SCHEDULE SCHEDULE A

Protocol No: TAK-226-3001

Country: India

Institution: Tata Medical Center, 14 Major Arterial Road (EW), Newtown, Rajarhat, Kolkata –700160, West Bengal, India ~~Enter Institution as included in CTA~~

Investigator: Dr. Arijit Nag

Tata Medical Center, 14 Major Arterial Road (EW), Newtown, Rajarhat, Kolkata – 700160, West Bengal, India ~~Enter Principal Investigator as included in CTA~~

Contracting Party:

- 1. Payment Method:** All amounts stated in Schedule A-1 are in Indian Rupees and payments will be made in Indian Rupees ("INR") by electronic bank transfer.
- 2. Requirements for payment:** No payments will be made under this Agreement to the Payee until the following are completed: (1) Execution of the Agreement, (2) Submission of all regulatory documents to Sponsor or CRO, (3) EC/IRB approval. No payments shall be made under this Agreement for obligations or entitlements that are covered or fulfilled under any other existing agreement between the Parties.
- 3. Payments should be made to:** The Parties agree that the Payee designated below is the proper Payee for this Agreement, and that payments under this Agreement will be made only to the following Payee (the "Payee"). Investigator and Institution acknowledge that if Investigator and/or Institution is not the Payee, CRO will not pay Investigator or Institution even if the Payee fails to reimburse Investigator and/or Institution.

~~**[Instructional Note:** Incorporate the following if a third-party other than the Institution is named the Payee. Please delete the paragraph above and this instructional note before sharing the draft with Site.]~~

~~[The Institution nominates and designates [insert the defined name of Research Company/ third-party payee] as the proper and authorised party for this Agreement to manage and receive all Study payments for and on behalf of the Institution ("Payee"). The Institution must ensure that [insert the defined name of Research Company/ third-party payee] complies with the requirements of Schedule A Budget & Payment Schedule to avoid any payment interruptions. On basis of the Institution's requirements and assessment, it has been agreed that all payments under this Agreement shall be made exclusively to the Payee and not the Institution, and the Institution has provided a separate no objection certificate to such payment arrangement ("NOC") in Schedule .]~~

~~**[Instructional Note:** Incorporate the following if the third-party payee is with a different name that does not match the pan card and/or the GST Certificate. Please delete this instructional note before sharing the draft with Site.]~~

~~[The Institution and Tata Medical Centre Trust [insert defined name of the SMO/ Research Company/ third-party payee] represent and warrant that: (i) the Payee named below is that of Tata Medical Centre Trust [insert defined name of the SMO/ Research Company/ third-party payee]; (ii) the bank account listed below is used by the Tata Medical Centre Trust [insert defined name of the SMO/ Research Company/ third-party payee] for payments related to clinical trial activities under this Agreement; and (iii) Tata Medical Centre Trust [insert defined name of the SMO/ Research Company/ third-party payee] owns this bank account. IQVIA reserves the right to withhold payments if any discrepancies are noted in the Payee and bank account details.]~~

PAYEE NAME

Tata Medical Centre Trust ~~[Insert Payee Name]~~

Formatted: Left

Formatted: Font color: Text 1, Complex Script Font: Not Bold

PAYEE ADDRESS	14 Major Arterial Road (EW) [Insert Payee Address]
	Newtown, Rajarhat [Insert Payee Address]
	Kolkata – 700160, West Bengal, India [Insert Payee City, State and Postal Code]
PAYEE CONTACT	Sanjeev Kumar Agarwal, Chief Financial Officer [Insert Name of Person at site]
PAYEE EMAIL ADDRESS	[Insert Payee Email Address]
BANK NAME	HDFC BANK LIMITED [Insert Bank Name]
BANK ADDRESS	Fort Mumbai, Manekji Wadia Building, Ground Floor, Nanik Motwani Marg, Mumbai – 400001, Maharashtra, India [Insert Bank Address]
BANK ACCOUNT NUMBER	00601660000021 [Insert Bank Account Number]
GST NUMBER	GSTIN: 19AABTT2222Q1Z3 [Insert VAT/Tax ID Number]
PERMANENT ACCOUNT NUMBER (PAN)	AABTT2222Q

Commented [TC1]: Need to be verified

In case of changes to the above Payee Address or Contact only, Payee must inform CRO by notifying in writing or email to apac@ctp.solutions.iqvia.com and will not require an amendment.

The Parties agree that changes to the Payee Name or VAT/GST number will require an amendment to the Agreement.

4. **Proforma and Payment Term:** Ongoing Subject Visit payments will be made in accordance with the attached Schedule A-1, on a per Subject, per visit basis, based upon prior Completed Visit data entered into the electronic Case Report Forms (“eCRFs”). Invoiceable payments will be made in accordance with the attached Schedule A-1. Sponsor/ CRO shall send the Proforma to the Institution. The Institution shall complete a Valid Invoice based on the Proforma and return to CRO/ Sponsor.

Payee will be reimbursed quarterly within thirty (30) days upon CRO's receipt of a Valid Invoice, where required by region, which clearly identifies the following:

- Payee details
- Invoice Number and date
- Name, phone number, and email address of contact to which queries can be directed
- Protocol number
- Investigator Name
- Site Number
- Date of activity, Subject Number (*if applicable*), and description of services provided
- Supporting documentation (*if applicable*)
- GST number for Payee (*if applicable*)
- Any information required under applicable law to be included on the invoice submitted by Payee

Invoices must be addressed and submitted to:

IQVIA RDS (India) Private Limited

Omega Embassy Tech Square Marathahalli – Sarjapur, Outer Ring Road,
Kadubeesanahalli, Bangalore- 560103, Karnataka, India
IQVIA GST number: KARNATAKA- 29AAACQ0935H1ZG

Email (Preferred): apac@ctp.solutions.iqvia.com

Sponsor to be copied: Global.SiteInvoices@Takeda.com

Please note that invoices will not be processed unless they are sent to this address, are non-disputed, itemized and include the details listed above ("Valid Invoice"). Failure to follow the requirements may result in delayed payment.

- 5. Applicable Taxes:** Institution undertakes to provide CRO with an invoice, to be sent to CRO at the address mentioned in this Section 4 of this Schedule A, in respect of such taxable services and such invoice shall be in accordance with the terms of the applicable tax laws in India, as may be amended from time to time or any successor legislation.

The Institution shall pay all applicable governmental sales taxes, use taxes, GST, or other similar taxes, duties, fees, levies or other governmental charges now in force or enacted in the future, as applicable. The Institution must also make payments of GST or other applicable taxes to the government authorities before the statutory due dates.

It should be noted that all payments made to the Payee are subject to Tax Deducted at Source (**TDS**) in accordance with the Indian tax laws, as amended from time to time. CRO will deduct the tax at the time of making payments unless a valid Certificate of no deduction or NIL deduction is obtained from the tax authority and made available to CRO.

All amounts specified in this Agreement are in Indian Rupees (**INR**) and are exclusive of any taxes and duties including Goods and Services Tax (**GST**). Institution shall pay any other taxes that are imposed by legislation in connection with the provision of services. CRO will pay to the Payee any amount of GST that the Payee is required to pay in addition to the amounts set out in this Schedule A and in accordance with the relevant Goods and Services Tax (GST) Act and its associated rules ("**GST Law**").

Institution shall file GST returns promptly following issuance of invoices to CRO and in any event no later than the statutory deadline. If Institution fails to file the returns by the statutory deadline, causing the the GST invoiced by Institution to not appear on the CRO GST portal within the GSTN portal, within sixty (60) days of raising an invoice to CRO, CRO reserves the right to recover the GST amount invoiced from Institution. Institution shall comply with its obligations under the applicable tax laws including GST and TDS. If CRO or Sponsor suffers any financial losses, resulting from Institution's non-compliance with its obligations under the applicable tax laws, CRO and Sponsor reserve the right to recover such financial losses from Institution, along with applicable interests.

Institution shall ensure that valid tax invoices are issued in strict accordance with the invoicing instructions outlined in this Section 4, including the e-invoicing requirements. If the services rendered are taxable under the GST Law, Institution shall ensure that the details required by the GST Law, such as the GST number, HSN code for services, and QR code/ IRN number (if applicable), are displayed on the invoices issued. Additionally, the tax invoices or any debit or credit notes issued must be uploaded to the GSTN portal within the prescribed timelines. Institution shall ensure that it includes the transactions with CRO under this Agreement in its periodic statutory returns filed within the prescribed timelines as required by the relevant and applicable GST Law. Institution shall further ensure that all taxes due as per the return have been duly

remitted in the manner prescribed by applicable laws. Non-compliant invoices will be rejected with reasons by CRO. Institution shall send revised invoices or debit/ credit notes, as appropriate, to CRO for any non-compliant invoices within seven (7) days of such non-compliant invoices. Institution acknowledges that this is a mandatory requirement to ensure compliance with the GST Law. If GST is exempted, Institution shall produce the necessary certificates and declarations evidencing the GST-exempted status to CRO.

Any mismatch reported by the GSTN portal due to errors by Institution must be reconciled and resolved by Institution within the prescribed time. In cases where CRO is unable to avail input tax credit for the GST amount paid or is denied such credit due to mismatches on the GSTN portal, non-payment of GST to the government, non-filing of GST returns, non-uploading of invoices within the due timelines, or other reasons attributable to Institution's failures (including e-invoicing requirements), Institution agrees that CRO has the right to offset such amounts (along with interest and penalties payable to the government authorities) from any amounts already due or that will become due and payable to Institution under this Agreement or any other agreement (to be agreed in writing in advance). Additionally, CRO reserves the right to recover the amount from Institution for which the input tax credit of GST could not be availed, along with any interest and penalties charged by the government on CRO for such defaults by Institution, by raising a debit note. Institution will be responsible for making payment against such a debit note within fifteen (15) days from the date of issuance.

Institution understands and agrees that if, at any later date, any error is found in the invoices issued, Institution shall be required to rectify the erroneous invoices by issuing debit/ credit notes to CRO as applicable.

Institution shall indemnify, defend and hold harmless CRO and its affiliates, and its and their directors, officers, employees, independent contractors, successors and assigns and agents (each, an "**CRO Indemnatee**"), from and against any and all losses, claims, damages, liabilities, fines, reasonable attorney fees, court costs, demands and expenses (collectively "**Losses**"), resulting or arising from any third-party claims, actions, proceedings, investigations (including subpoenas or other legal process) or litigation relating to or arising from or in connection with, any tax implications, challenges, or queries that may be raised by the government authorities including the tax authorities, provided that such Losses are determined to have resulted from Institution's GST non-compliance, and failure to comply with the GST Law and the terms and conditions of this Schedule A.

- 6. Screen Failures:** Payee will be compensated up to four (4) Screen Failures. Payee will be reimbursed at the total cost of the Screening visit (per Screen Failure) wherein the subject Screen Fails. Payment of additional Screen Failures shall be subject to written approval from the Sponsor but does not require an amendment to the Agreement.

For purposes of this Agreement, a Screen Failure shall mean a subject who (i) completes the Screening Visit procedures outlined in the Protocol (including, without limitation, the informed consent process) and (ii) is not randomized. To be eligible for reimbursement of Screening Visit, completed screening eCRF pages must be entered into the EDC. CRO will not reimburse for any procedures carried out after the subject has failed screening.

- 7. Unscheduled Visits:** For purposes of this Agreement, an "Unscheduled Visit" means a Subject visit which is not expressly set forth in the schedule of Study procedures of the Protocol, but that (i) may be required for the Study as directed by the Investigator, or (ii) may be related to an adverse event experienced during the Study or otherwise required for the Study as directed by the Investigator, for the health and welfare of a Subject. Standard of care subject visits or procedures that are not required by the Protocol do not constitute Unscheduled Visits for purposes of this Agreement.

Unscheduled Visits will be reimbursed on a per subject, per visit basis in accordance with the Unscheduled Visit rates set forth in Schedule A-1. In case additional procedures are required at the Unscheduled Visit, the Institution will be reimbursed at the procedure rates set forth in Schedule A-1. Unscheduled Visits will be paid upon receipt of a Valid Invoice and/or upon confirmation of data entry. In the event that reimbursement rates for medically necessary procedures are not included in Schedule A-1, the amount of reimbursement for those procedures will be reviewed in good faith by Sponsor prior to Sponsor's approval or disapproval of the expenditures, which shall not unreasonably be withheld or delayed.

- 8. Subject Stipend/ Compensation:** Subject stipend/compensation for each completed study visit may be paid directly to the Subject through a third-party vendor as specified in the ICF.

Alternatively, Subject stipend/compensation may be paid to the Subject through Institution in accordance with the rates set forth in the budget based on completed visits. In the event that any subject stipend/compensation is paid by CRO to the Institution but not actually paid to the Subject, Institution will refund that amount to CRO within forty-five (45) days of request. No overhead shall be applied.

- 9. Subject Travel Reimbursement:** Reimbursement for study visit related travel expenses should be made in accordance with the ICF. Reimbursement for study visit related travel expenses (i.e., travel/mileage, meals, parking, etc.) for each completed study visit may be paid directly to the Subject through a third-party vendor.

Alternatively, Institution may reimburse the Subject for their travel expenses as actually incurred due to their participation in the Study. Reimbursement will be payable upon receipt of Valid Invoice and adequate proof of the expenses incurred. In the event that any subject travel reimbursement is paid by CRO to the Institution but not actually paid to the Subject, Institution will promptly refund that amount to CRO. No overhead shall be applied. Subjects must have travelled to site on the visit day to receive reimbursement.

Any Subject who will incur travel expenses exceeding the amounts listed in Schedule A-1 shall be subject to the prior written approval of the Sponsor but does not require further amendment to the Agreement.

- 10. Final Payment:** The Final payment (inclusive of all close out fees as listed in the Schedule A-1) will be payable upon completion of the close out visit and upon Sponsor's final acceptance of the following: (i) all Study documentation, (ii) the accountability of any unused Study Drug, (iii) any equipment provided to Institution by Sponsor, (iv) all completed and correct eCRFs/queries, (v) resolution of any clarification requests made by CRO or Sponsor regarding Study data or records and (vi) upon satisfaction of all other applicable conditions set forth in this Agreement (hereinafter "Final Payment"). All final invoices must be submitted by the Payee within sixty (60) days of the close out visit. Any invoices received after this timeframe will not be eligible for payment by CRO or Sponsor. The Payee will have up to sixty (60) days from the receipt of Final Payment to dispute any Study payment discrepancies.

If the total amount that CRO has paid exceeds the amount to which Payee is entitled hereunder, Payee shall return the overpayment to CRO within forty-five (45) days of receipt of CRO's written notification of the amount due.

- 11. Additional Funding Requests:** The amounts listed within Schedule A-1 include all applicable taxes and overhead, unless otherwise stated. No further funding requests will be provided unless requested in writing and approved by Sponsor.

12. Equipment: The Institution may be supplied with, if needed: [insert any equipment] (where applicable for selected sites) (collectively, "Equipment")

All Equipment shall be provided by the Sponsor or CRO/vendors contracted by the Sponsor, and shall remain the sole property of Sponsor, or CRO /vendor, as the case may be.

Therefore, it is hereby agreed that such Equipment shall:

- a) be subject to removal at any time upon the Sponsor's or, CRO's demand provided that such removal does not prevent the Institution from conducting the Study and carrying out their obligations under this Agreement;
- b) be used only for the purposes of the Study;
- c) be used in accordance with any manuals or instructions while in possession of the Institution;
- d) shall remain in the same condition, ordinary wear and tear excepted. As long as the Equipment are in the possession of the Institution, it is liable for maintenance or any risk of loss in connection with the Equipment during the conduct of the Study;
- e) be clearly identified as the sole property of the Sponsor/CRO/vendor, as applicable, by clearly stating "BELONGS TO Name of legal owner" in order to notify any third parties, including creditors, that the legal owner retains title thereto; and
- f) upon completion or termination of the Study, CRO or Sponsor, together with Institution assistance, shall arrange the return of all Equipment provided for the Study within one (1) month of request to return, or if requested by the Sponsor or CRO in writing, arrange for the disposal of the Equipment as soon as reasonably practicable, and certify to Sponsor or CRO that such disposal has been done.

Institution shall be responsible for the safekeeping of Equipment while Equipment is in Institution's possession. Sponsor, or its designee, shall be responsible for regular required maintenance of the Equipment as per the user's manual, as well as replacing parts due to ordinary wear and tear.

During the time Equipment is in the possession of the Institution, Institution shall be responsible for any loss of, or damage to the Equipment (minus ordinary wear and tear), except to the extent such loss or damage is due to the acts and/or omissions of Sponsor and/or CRO. Upon completion or termination of the Study, CRO or Sponsor, together with Institution's assistance shall arrange the return of all Equipment within one (1) month of written request to return.

Notwithstanding the foregoing, it is hereby acknowledged that Institution may be performing other studies sponsored by Sponsor that involves the use of Equipment ("Other Takeda Study"). Sponsor shall provide Equipment for Institution's use as set forth in the clinical trial agreement for each such Other Takeda Study. The parties agree that the obligations of Institution to return the Equipment as set forth herein shall not apply in the event one or more Other Takeda Study is underway at Institution, or as otherwise authorized in writing by Sponsor.

Schedule A-1 to the Clinical Study Agreement

The Budget is as follows:

Elriterccept Dosing:

Procedure		Screening			Screening Period
Informed Consent	Yes	Day 1	Cycle 1	Treatment Period	
Randomization	Yes	Day 8			
Elritercept Dosing	Yes	Day 15			
	Yes	Day 1	Cycle 2		
		Day 15			
	Yes	(Week 9) Day 1	Cycle 3		
		Day 8			
		Day 15			
	Yes	Day 1	Cycle 4		
		Day 8			
		Day 15			
	Yes	Day 1	Cycle 5-6		
		Day 15			
	Yes	(Week 25) Day 1	Cycle 7		
		Day 15			
	Yes	Day 1	Cycle 8-12		
		Day 15			
	Yes	Day 1	Cycle 13+		
		Day 15			
End of Treatment					
		28D Post Last Dose	Safety	Follow-Up	
60D Post Last Dose					
		Quarterly From Last Dose	Survival		
		UNS visit			

Selected Cost Per Visit	52291	49583	36128	31441	48535	31441	45009	31441	31441	48535	36128	31441	47889	31441	96300	31441	47889	31441	52421	31441	94147	38241	38886	11814	24279
Total Cost Per Subject	1026762																							24279	

Epoetin Alfa Dosing:

Randomization	Informed Consent	Procedure	Screening		Screening Period
			Day 1	Cycle 1	Treatment Period
Yes			Day 8		
			Day 15		
			Day 1	Cycle 2	
			Day 15		
			(Week 9) Day 1	Cycle 3	
			Day 8		
			Day 15		
			Day 1	Cycle 4	
			Day 8		
			Day 15		
			Day 1	Cycle 5-6	
			Day 15		
			(Week 25) Day 1	Cycle 7	
			Day 15		
			Day 1	Cycle 8-12	
			Day 15		
			Day 1	Cycle 13+	
			Day 15		
			End of Treatment		
			28D Post Last Dose	Safety	Follow-Up
			60D Post Last Dose		
			Quarterly From Last Dose	Survival	
			UNS visit		

Pharmacy Dispensing (Epoetin Alfa)		Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes					
Selected Cost Per Visit (INR)	52291	49583	42100	34320	48535	34320	47889	34320	34320	48535	42100	34320	47889	34320	96300	34320	47889	34320	52421	34320	94147	38241	38886	11814	24279
Total Cost Per Subject (INR)	1067499																							24279	

Site Fees (One-time fee inclusive of Overhead)	Payment Trigger	Payment Frequency	Selected Cost
Study Start Up Fee (will be paid post site-initiation)	Invoice	1	59244
Pharmacy set-up fee	Invoice	1	42070
Lab set-up fee	Invoice	1	36865

Close-Out Fees (One-time fee inclusive of Overhead)	Payment Trigger	Payment Frequency	Selected Cost
Study Close-out Fee	Completion of Close-Out visit - Invoice	1	46066
Pharmacy Close-out fee	Completion of Close-Out visit - Invoice	1	16670
Archiving/Document storage (for 15 years)	Completion of Close-Out visit - Invoice	1	113377

Other Site Fees (inclusive of Overhead)	Payment Trigger	Payment Frequency (Per Patient)	Selected Cost
Subject Reconsent	Invoice	Per Occurrence	2217
Chart Review fee	Per report - Invoiceable	20	2194

Invoiceable Fees (inclusive of Overhead)	Payment Trigger	Payment Frequency (Per Patient)	Selected Cost (With OH)
Echocardiogram (Transthoracic) with Interpretation and Report: (To be invoiced at C13D1 and every 6 months thereafter during trial intervention)	EDC	10	43233
Echocardiogram (Transesophageal) with Interpretation and Report: (To be invoiced at C13D1 and every 6 months thereafter during trial intervention)	EDC	10	35486
Bone Marrow Core Biopsy (Includes Prep Time & Effort) (To be invoiced if applicable at screening, C7D1)	EDC	Per Occurrence	8588
Bone Marrow Aspiration (Includes Prep Time & Effort) (To be invoiced if applicable at screening, C7D1 and C13D1)	EDC	Per Occurrence	6054
Peripheral blood smear (To be invoiced if applicable at screening, C7D1, and C13D1)	EDC	Per Occurrence	739
Anesthesia for bone marrow aspiration and/or biopsy (To be invoiced if applicable at screening, C7D1, and C13D1)	Invoice	Per Occurrence	13537
Transfusion Verification - Medical Records Retrieval	Invoice	Per Occurrence	3400
Hotel (Per Night) (Cost up to amount)	Invoice	Per Occurrence	6000
Travel reimbursement (Cost up to amount)	Invoice	Per Occurrence	2000
Meals (Cost up to amount)	Invoice	Per Occurrence	433

Conditional Fees (inclusive of Overhead)	Payment Trigger	Payment Frequency (Per Patient)	Selected Cost (With OH)
Pregnancy Test Urine	EDC	12	904
Pregnancy Test Serum	EDC	1	2715
STRAIN Echocardiogram	EDC	Per Occurrence	4057
Echocardiogram (Transthoracic) with Interpretation and Report (To be invoiced at screening if repeated to be within the protocol defined timepoint)	EDC	1	43233
Echocardiogram (Transesophageal) with Interpretation and Report: (To be invoiced at screening if repeated to be within the protocol defined timepoint)	EDC	1	35486
Bone Marrow Core Biopsy (Includes Prep Time & Effort) (To be invoiced if optional biopsy performed at C13D1, at EOT if >6 months since prior collection and as clinically indicated)	EDC	Per Occurrence	8588
Bone Marrow Aspiration (Includes Prep Time & Effort) (To be invoiced at EOT if >6 months since prior collection and as clinically indicated)	EDC	Per Occurrence	6054
Peripheral blood smear (To be invoiced at EOT if >6 months since prior collection and as clinically indicated)	EDC	Per Occurrence	739
Anesthesia for bone marrow aspiration and/or biopsy (To be invoiced at EOT if >6 months since prior collection and as clinically indicated)	Invoice	Per Occurrence	13537
Hematology Panel (If performed locally)	Invoice	Per Occurrence	1563
Chemistry Panel (If performed locally)	Invoice	Per Occurrence	4100
Coagulation Panel (If performed locally)	Invoice	Per Occurrence	3535
Urinalysis (If performed locally)	Invoice	Per Occurrence	646
Tissue Slide Prep (Includes staining, preparation, shipping and handling) (To be invoiced if applicable every 6 months post W49 through EOTx)	EDC	Per Occurrence	3521

Schedule B

DATA PROTECTION SCHEDULE

Data Protection Requirements

The following terms between Sponsor and Institution reflect what is agreed between them, both acting as Data Controllers, to facilitate the processing and sharing of Personal Data. The terms define the data protection principles that Sponsor and Institution shall adhere to and their responsibilities to each other.

1. Definitions

The terms “Controller”, “Data Subject”, “Personal Data”, “Processor”, “Processing” and “Supervisory Authority” shall have the same meaning as in the applicable Data Protection Law. For avoidance of doubt, applicable Data Protection Law means all Applicable Law in relation to data protection, privacy, interception and monitoring of communications, or requirements relating to the Processing of Personal Data, including but not limited to the General Data Protection Regulation EU 2016/679.

“Security Incident” shall mean any actual or reasonably suspected accidental, unlawful or unauthorised loss, destruction, alteration, access, use, disclosure of, damage or corruption to Personal Data Processed under this Agreement.

2. Identification of the Controllers

2.1. Sponsor is the Controller for key-coded Personal Data of Study subjects collected and transferred by the Institution in accordance with the Protocol and the informed consent form, as approved by the IEC and Sponsor; and Personal Data of Study Personnel collected in accordance with this Agreement.

2.2. Institution and/or Investigator is/are responsible for the collection (and where applicable, the coding) of Personal Data under the Study and act(s) as Controller for medical records possessed by Institution with respect to source data and/or Personal Data disclosed by Data Subjects in the course of treatment and Personal Data collected or generated in the course of the Study for the purpose of exercising independent medical judgment in line with the Agreement and Protocol.

3. Warranties. Fair and Lawful Processing

3.1. Sponsor and Institution shall at all times comply with their respective obligations under all applicable Data Protection Law in connection with this Agreement.

3.2. Sponsor and Institution shall not process Personal Data for any other purpose than those established under this Agreement, unless authorized or required to do so by Applicable Law, as required to establish or defend legal claims, as authorized by the other, or for obtaining appropriate consent from the Data Subject.

3.3. Investigator/Institution represents and warrants that it will provide an appropriate data privacy notice and obtain appropriate consent (if legally required) from the Data Subjects and that such notice (and consent if appropriate) is in accordance with language approved by Sponsor and IEC and allows for the desired uses of such Personal Data under this Agreement. Should Sponsor or Institution learn that it has provided Personal Data under this Agreement that may not be shared pursuant to a consent or notice, it is responsible for promptly notifying the other so that the affected Personal Data under this Agreement can be deleted, as required.

3.4. Sponsor and Institution shall ensure that the access to the Personal Data under this Agreement is limited to its personnel who need to have access to it for the performance of the obligations under this Agreement, and that such personnel are subject to confidentiality obligations.

3.5. Sponsor and Institution shall each apply appropriate technical and organisational security measures reflective of current good industry practice and technological development to protect Personal Data under this Agreement against any Security Incident.

4. Data Subject Rights

4.1. Sponsor and Institution agree that the responsibility for responding to Data Subject rights requests from Study subjects falls on the Institution, and that it will forward any Data Subject Requests it is unable to address itself to Sponsor.

4.2. Sponsor and Institution agree to cooperate and provide reasonable assistance as is necessary to each other to comply with applicable Data Protection Law, comply with Data Subject Requests and respond to any other queries or complaints from Data Subjects.

5. Data Retention

Sponsor and Institution agree that they shall not Process the Personal Data under this Agreement for longer than necessary to fulfil the responsibilities described in this Agreement, as outlined by the Protocol and the applicable informed consent form, and as required by Applicable Law.

6. Transfers

Each of Sponsor and Institution may transfer the Personal Data under this Agreement to its third parties to the extent such third parties have a legitimate need to process the Personal Data under this Agreement, provided that such transfers are subject to appropriate contractual restrictions and are made in accordance with Applicable Data Protection Law. The Sponsor and Institution shall not disclose or transfer Personal Data outside the European Economic Area without affording adequate protections for Personal Data in accordance with applicable Data Protection Law.

7. Security Incidents

7.1. In the event Institution suffers a Security Incident affecting the Personal Data related to the Study under this Agreement, Institution shall ensure it complies with Data Protection Law, including any obligations to notify the Supervisory Authority, Data Subjects, or other regulatory bodies as required by Data Protection Law.

7.2. To the extent the Institution suffers a Security Incident that has an impact on the Personal Data related to the Study under this Agreement, Institution shall promptly notify Sponsor of such Security Incident and, in any event, within 48 hours of discovery of a Security Incident.

8. Compliance

Upon request from Sponsor, Institution shall make available all relevant information necessary to demonstrate compliance with Data Protection Law, including but not limited to a copy of any independent auditor's report which relates directly to Institution's performance under this Agreement (to be made not more than once annually).

9. Personal Data of Study Personnel

Prior to and during the course of the Study, the Sponsor may request the collection of Personal Data of the Study Personnel. Institution agrees to assist Sponsor with obtaining any consents, or providing any notice, as may be required by Applicable Law.

SCHEDULE C EQUIPMENT SUPPLY

This Schedule C, Equipment Supply (this “**Schedule**”) is part of the Takeda Sponsored Clinical Trial Agreement (including its schedules) (“**Agreement**”) for the Study and shall be treated as part of the Agreement. Unless otherwise provided in this Schedule, the capitalized terms used herein shall have the same meaning assigned to them in the Agreement.

1. In the event that any equipment or device (“Equipment”) will be provided by the Sponsor (or through the CRO or a third party as designated by the Sponsor) to the Institution for the purpose of the Study, the Institution and the Sponsor (through CRO) shall specify and confirm the particulars of such Equipment and keep clear, proper and auditable record of the Equipment (including its status) (“**Equipment Records**”).
2. During the Study, if there is any change to the Equipment provided by the Sponsor (or through the CRO or a third party as designated by the Sponsor) to the Institution, including any change to the specifications and number of Equipment, or adding new Equipment or reducing existing Equipment, etc., the Institution (through the Investigator) and the Sponsor (through CRO) shall update Equipment Records, which shall replace any earlier version.
3. In order to avoid any doubt, it is at the Sponsor’s sole discretion whether to provide any Equipment to the Institution for the Study, and there is no obligation for the Sponsor to provide any Equipment to the Institution.
4. All Equipment provided hereunder shall remain the sole property of the Sponsor or a third party as designated by the Sponsor (as the case may be) and the supply of the Equipment to the Institution does not transfer any ownership of the Equipment to the Institution. The Institution shall use the Equipment only for the performance of the Study or other overlapping Sponsor’s or its affiliate’s studies as approved by Sponsor in writing.
5. Upon receipt of the Equipment by Institution, Institution shall check the Equipment and accept the Equipment properly and sign the handover documents for the Equipment. Institution shall be responsible for the safekeeping of Equipment while Equipment is in Institution’s possession.
6. Institution shall ensure that:
 - a) Equipment shall be used only for the purposes of the Study or other overlapping Sponsor’s or its affiliate’s studies as approved by Sponsor in writing;
 - b) Equipment shall be used in accordance with any manuals or instructions associated with the Equipment or provided by the Sponsor (or CRO) while in possession of the Institution; and
 - c) Equipment shall be clearly identified as the sole property of the Sponsor or a party as designated by Sponsor (as the case may be), as applicable, by stating “BELONGS TO [Name

of legal owner]" in order to notify any third parties, including creditors, that the legal owner retains title thereto.

7. During the time when Equipment is in the possession of the Institution, Institution shall be responsible for any loss of, or damage to the Equipment (minus ordinary wear and tear), except to the extent such loss or damage is due to the fault of Sponsor and/or CRO. Sponsor or its designee, shall be responsible (where applicable) for regular required maintenance of the Equipment as pursuant to the users' manual, as well as replacing parts due to ordinary wear and tear.
8. The Parties agree that Sponsor (itself or through CRO or any third party as designated by the Sponsor) is entitled to request Institution to return any or all of the Equipment at any time by providing Institution with prior written notice. Upon the receipt of the return notice from the Sponsor (or CRO or any third party as designated by the Sponsor), Institution shall immediately return the Equipment to the Sponsor (or CRO or any third party as designated by the Sponsor).
9. At the conclusion of the Study, unless otherwise agreed to by the Sponsor in writing, the Institution shall return the Equipment to the Sponsor or its designee, transfer the Equipment to another overlapping study (if any) at the Institution as approved by the Sponsor in writing, or properly dispose the Equipment (providing certification to Sponsor or CRO that such disposal has been done) as soon as reasonably practicable as requested by the Sponsor or CRO in writing.

Attachment A
NO OBJECTION CERTIFICATE

We acknowledge and confirm that the Site requires all payments related to the Study, i.e., payments for clinical trial activities conducted at this Site for the Protocol, to be made to the following bank account. The Site also confirms that the bank account listed below is used for all Study-related payments. The bank account is owned by Tata Medical Centre TrustXXXX, and the Site expressly confirms that it has no objections to this payment arrangement:

Protocol Number	TAK-226-3001
Protocol Title	A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions
Payee Name	<u>Tata Medical Centre Trust</u>
Payee Address	<u>14 Major Arterial Road (EW), Newtown, Rajarhat, Kolkata – 700160, West Bengal, India,</u>
Payee Remittance Email Address	
Bank Name	<u>HDFC BANK LIMITED</u>
Bank Street Address	<u>Fort Mumbai, Manekji Wadia Building, Ground Floor, Nanik Motwani Marg, Mumbai – 400001, Maharashtra, India</u>
Bank Account #	<u>00601660000021</u>
IFSC code	<u>HDFC0000060</u>
Name on PAN	<u>Tata Medical Centre Trust</u>
Permanent Account Number (PAN) of Payee	<u>AABTT2222Q</u>
GST Number	<u>19AABTT2222Q1Z3</u>
Trade Name on GST Certificate	<u>Tata Medical Centre Trust</u>
Legal Name on GST Certificate	<u>Tata Medical Centre Trust</u>
Mode of Payment	Electronic Fund Transfer

Formatted: Font color: Text 1

INSTITUTION:

Signature: _____

Print Name: Dr. P. Arun

Title: CEO

Date: _____

Stamp:

PRINCIPAL INVESTIGATOR:

Signature: _____

Print Name: Dr. Arijit Nag

Title: Principal Investigator

Date: _____

Stamp: